Multiple phase 3 studies found that lebrikizumab improved face and hand dermatitis in a majority of patients at 16 weeks and maintained a stable response through 52 weeks, Eli Lilly and Company announced in a press release.
“These two localizations of atopic dermatitis are the most burdensome, and the stigmatization of them is high mostly because they are highly visible parts of the body,” Lotus Mallbris, MD, PhD, senior vice president of global immunology development and medical affairs at Lilly, told Healio. “This data is really significant as we see both improvement and